Allogene’s Early MRD Breakthrough | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070416

Show notes

Allogene Therapeutics is accelerating its ALPHA3 trial to treat lymphoma earlier using MRD-guided therapy with Cema-Cel, showing rapid clearance in early data and enabling outpatient care—even for patients without prior CAR-T experience. FDA RMAT and Fast Track designations validate the approach for first-line consolidation, targeting a critical unmet need. The company has expanded to over 80 active clinical sites, with 100 expected by year-end, fueled by investigator enthusiasm and growing MRD adoption. Meanwhile, ALLO-316 shows promise in solid tumors, while ALLO-329’s RESOLUTION trial enrolls quickly, with key updates due by year’s end—all reinforcing Allogene’s mission to deliver accessible, allogeneic CAR-T innovation. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/677611f2241a4efa

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.